# US 2019/0316213 A1 · Validation of continuous viral clearance

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0316213 A1
- Document ID: US20190316213A1
- Status: Published application
- Kind: A1
- Application number: 16/343,125
- Filed: 2017-10-20
- Published: 2019-10-17
- Earliest claimed: 2016-10-21
- Assignees: Bayer Aktiengesellschaft
- Applicants: Bayer Aktiengesellschaft
- Inventors: Benjamin MAISER; Peter SCHWAN; Laura DAVID; Martin LOBEDANN
- Web page: https://patentgrep.com/patent/US20190316213A1

## CPC

- C12Q 1/22: Testing for sterility conditions
- C12Q 1/701: {Specific hybridization probes}
- C07K 1/14: Extraction; Separation; Purification
- C07K 1/16: by chromatography
- C07K 1/36: by a combination of two or more processes of different types
- A61L 2/08: Radiation
- A61L 2/16: using chemical substances
- A61L 2103/05: Living organisms or biological materials
- G01N 2333/005: from viruses
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Disclosed herein is a method for validation of continuous viral clearance comprising the steps of providing a probe to be validated, spiking the probe in a valid manner, performing viral clearance, sampling the spiked probe and analyzing the sample of the spiked probe of step d).

## Claims

### Claim 1

A method for validation of continuous viral clearance comprising
a) providing a probe to be validated,
b) spiking the probe in a valid manner
c) performing viral clearance,
d) sampling the spiked probe and
e) analyzing the sample of the spiked probe of d).

### Claim 2 (depends on 1)

The method according to claim 1, wherein the probe is a stream and/or a product stream.

### Claim 3 (depends on 1)

The method according to claim 1, wherein d) sampling the spiked probe comprises sampling for a predetermined period of time.

### Claim 4 (depends on 1)

The method according to claim 1, wherein b) spiking the sample in a valid manner comprises spiking the sample after homogenization.

### Claim 5 (depends on 1)

The method according to claim 1, wherein in c) the viral clearance is a viral inactivation.

### Claim 6 (depends on 1)

The method according to claim 1, wherein in c) the viral clearance is a viral inactivation which is carried out in a CFI.

### Claim 7 (depends on 1)

The method according to claim 1, wherein sampling the spiked probe comprises back to front sampling.

### Claim 8 (depends on 1)

The method according to claim 1, wherein sampling the spiked probe comprises immediately neutralized each probe drop when upon entering the sampling container.

### Claim 9 (depends on 1)

The method according to claim 1, wherein d) analyzing the sample of the spiked probe comprises determination whether viral particles are present.

### Claim 10 (depends on 1)

The method according to claim 1, wherein d) analyzing the sample of the spiked probe comprises quantification of the viral particles.

### Claim 11 (depends on 1)

The method according to claim 1 in a continuous process for the production of therapeutic proteins.
